Bristol-Myers Squibb's (BMY) Opdivo Demonstrates Superior Overall Survival in NSCLC
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) today announced that Opdivo (nivolumab) is the first PD-1 inhibitor to demonstrate superior overall survival ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE